Ira Zackon, MD

Ira Zackon, MD, discusses the real-world uptake of bispecific antibodies in community oncology practices and what it reveals about their utilization in relapsed/refractory multiple myeloma treatment.

Ira Zackon, MD, explains how clinicians can ensure clinical trial patient populations are more inclusive and minorities are better represented.

Ira Zackon, MD, discusses what strategies community oncology practices can implement to address racial and socioeconomic disparities in chronic lymphocytic leukemia.

Ira Zackon, MD, discusses the results of a real-world study evaluating racial and socioeconomic disparities among patients with chronic lymphocytic leukemia.

Ira Zackon, MD, discusses the background of a real-world study which sought to identify some of the racial and socioeconomic disparities seen in patients with chronic lymphocytic leukemia.